Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?'

Affiliations

¹ Division of Hepatology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Republic of Korea; The Catholic University Liver Research Center, Seoul, Republic of Korea.
² Division of Hepatology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Republic of Korea; The Catholic University Liver Research Center, Seoul, Republic of Korea. Electronic address: garden@catholic.ac.kr.

Comment

Hyun Yang et al. J Hepatol. 2023 Oct.

. 2023 Oct;79(4):e155-e157.

doi: 10.1016/j.jhep.2023.06.005. Epub 2023 Jun 27.

¹ Division of Hepatology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Republic of Korea; The Catholic University Liver Research Center, Seoul, Republic of Korea.
² Division of Hepatology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Republic of Korea; The Catholic University Liver Research Center, Seoul, Republic of Korea. Electronic address: garden@catholic.ac.kr.

No abstract available

Comment on

A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Yang H, Bae SH, Nam H, Lee HL, Lee SW, Yoo SH, Song MJ, Kwon JH, Nam SW, Choi JY, Yoon SK, Jang JW. Yang H, et al. J Hepatol. 2022 Sep;77(3):632-641. doi: 10.1016/j.jhep.2022.03.032. Epub 2022 Apr 7. J Hepatol. 2022. PMID: 35398462
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?
Carlson S, Vaz K, Peterson A. Carlson S, et al. J Hepatol. 2023 Oct;79(4):e154-e155. doi: 10.1016/j.jhep.2023.01.021. Epub 2023 Feb 1. J Hepatol. 2023. PMID: 36736735 No abstract available.